Mometadex (Mometasone Furoate Ph. Eur.)

Mometasone furoate, the active ingredient in Mometadex, is a corticosteroid presented as a nasal spray for nasal administration. It is used to treat inflammatory nasal conditions such as allergic rhinitis and nasal polyps in adults and adolescents.

GNH USA supplies Mometadex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometadex is a nasal corticosteroid that reduces inflammation in the nasal mucosa, helping control symptoms of several upper‑airway disorders.

- Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. - Nasal polyps: decreases polyp size and improves nasal airflow. - Seasonal allergic rhinitis: provides anti‑inflammatory relief during pollen seasons.

Mometadex may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Throat irritation or dryness. - Altered taste or bitter taste. - Cough.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe allergic reaction (anaphylaxis). - Visual disturbances or cataract formation. - Adrenal suppression with prolonged high‑dose use. - Opportunistic fungal infection of the nasal passages. - Elevated intra‑ocular pressure leading to glaucoma.

Before using Mometadex, consider the following safety measures.

- Assess for active nasal infection: avoid use if bacterial or fungal infection is present. - Monitor intra‑ocular pressure: caution in patients with glaucoma or ocular hypertension. - Use the lowest effective dose: limit systemic exposure and potential side effects. - Limit duration of therapy: follow prescribing guidance to avoid chronic use. - Pregnancy and lactation: consult a healthcare professional before use. - Store at room temperature: keep in the original container, protect from moisture and heat.

Mometadex may interact with other medicines that affect corticosteroid activity or metabolism.

Major Interactions (Avoid): - Concurrent systemic corticosteroids: may increase systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise local drug exposure.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., itraconazole): may modestly increase nasal steroid levels. - Immunosuppressants (e.g., cyclosporine): additive immunosuppression risk. - Live vaccines: potential reduced vaccine efficacy.